Obesity and chronic daily headache

Current Pain and Headache Reports

Volumn 12, Issue 1, 2008, Pages 56-61

  Bigal, Marcelo E ^a   Lipton, Richard B ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; GELATINASE B; LEPTIN; OREXIN A; RESISTIN; SIBUTRAMINE; SUMATRIPTAN; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM;

ADIPOCYTE; BEHAVIOR THERAPY; BODY MASS; CHRONIC DAILY HEADACHE; CHRONIC TENSION HEADACHE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; EXERCISE; FOOD INTAKE; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW CALORY DIET; MIGRAINE; MIGRAINE WITH AURA; NERVE STIMULATION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY HEADACHE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TRANSFORMED MIGRAINE; WEIGHT CONTROL; WEIGHT GAIN;

DISEASE PROGRESSION; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; OBESITY;

EID: 39049140838     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-008-0011-8     Document Type: Review

References (41)

1. Leonardi M, Steiner TJ, Scher AT, Lipton RB: The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability, and Health (ICF). J Headache Pain 2003, 6:429-440.
2. Lipton RB, Bigal ME, Diamond M, et al.: Migraine prevalente, disease burden, and the need for preventive therapy. Neurology 2007, 68:343-349.
3. Linet MS, Stewart WF: Migraine headache: epidemiologic perspectives. Epidemiol Rev 1984, 6:107-139.
4. Scher AI, Stewart WF, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497-506.
5. Lipton RB, Bigal ME: Migraine: epidemiology, impact, and risk factors for progression. Headache 2005, 45(Suppl 1):S3-S13.
6. Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102-106.
7. Silberstein SD, Lipton RB, Sliwinski M: Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871-875.
8. Kruit MC, van Buchem MA, Hofman PA, et al.: Migraine as a risk factor for subclinical brain lesions. JAMA 2004, 291:427-434.
9. Kurth T, Gaziano JM, Cook NR, et al.: Migraine and risk of cardiovascular disease in women. JAMA 2006, 296:283-291.
10. Welch KMA, Nagesh V, Aurora SK, Gelman N: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001, 41:629-637.
11. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al.: Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447-1455.
12. National Health and Nutrition Examination Survey, 2004. Available at http://www.cdc.gov/nchs/nhanes.htm. Accessed April 01, 2007.
13. Scher AI, Stewart WF, Ricci JA, Lipton RB: Factors associated with the onset and remission of chronic daily headacbe in a population-based study. Pain 2003, 106:81-88.
14. Bigal ME, Liberman JN, Lipton RB: Obesity and migraine: a population study. Neurology 2006, 66:545-550.
15. Bigal ME, Lipton RB: Obesity is a risk factor for transformed migraine but not for chronic tension-type headache. Neurology 2006, 67:252-257.
16. Bigal ME, Tsang A, Loder E, et al.: Body mass index and primary headaches. The AMPP study. Arch Intern Med 2007, 167:1964-1970.
17. Galuska DA, Serdula M, Pamuk E, et al.: Trends in overweight among US adults from 1987 to 1993: a multistate telepbone survey. Am J Public Health 1996, 86:1729-1735.
18. Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
19. Moskowitz MA: Basic mechanisms in vascular headache. Neurol Clin 1990, 8:801-815.
20. Cutrer FM, Yu XJ, Ayata G, et al.: Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 1999, 38:1043-1053.
21. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
22. Goadsby PJ, Macdonald GJ: Extracranial vasodilatation mediated by VIP (vasoactive intestinal polypeptide). Brain Res 1985, 329:285-288.
23. Sarchielli P, Alberti A, Baldi A, et al.: Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46:200-207.
24. Welch KM, Brandes AW, Salerno L, Brandes JL: C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006, 46:197-199.
25. D'Amico D, Moschiano F, Leone M, et al.: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998, 18:618-621.
26. Flier JS: The adipocyte: storage depot or node on the energy information superhighway? Cell 1995, 80:15-18.
27. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22:1145-1158.
28. Herishanu Y, Rogowski O, Polliack A, Marilus R: Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. Eur J Haematol 2006, 76:516-520.
29. Curat CA, Wegner V, Sengenes C, et al.: Macrophages in human visceral adipose tissue: increased accomulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
30. Gram DX, Hansen AJ, Wilken M, et al.: Plasma calcitonin gene-related peptide is increased prior to obesity, and sensory nerve desensitization by capsaicin improves Oral glucose tolerance in obese Zucker rats. Eur J Endocrinol 2005, 153:963-969.
31. Siegel JM: Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004, 55:25-48.
32. Baranowska B, Wolinska-Witort E, Martynska M, et al.: Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insolin in obese women. Neuro Endocrinol Lett 2005, 26:714.
33. Kajiyama S, Kawamoto M, Shiraishi S: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally administered orexins in diabetic neuropathic pain model rats. Brain Res 2005, 1044:76-86.
34. Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917-2921.
35. Bigal ME, Lipton RB, Holland PR, Goadsby PJ: Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007, 68:1851-1861.
36. VanItallie TB, Yang MU: Current concepts in nutrition: diets and weight loss. N Engl J Med 1977, 297:1158-1161.
37. Yang M, VanItallie TB: Effect of energy restriction on body composition and nitrogen balance in obese individuals. In Treatment of the Seriously Obese Patient. Edited by Wadden TA, VanItallie TB. New York: Guilford Press; 1992:83-106.
38. Stefanick ML, Mackey S, Sheehan M, et al.: Effects of the NCEP Step 2 diet and exercise on lipoprotein in postmenopausal women and men with low HDL-cholesterol and high LDL-cholesterol. N Engl J Med 1998, 339:12-20.
39. NIH Consensus Conference. Physical Activity and Cardiovascular Health. JAMA 1996, 276:241-246.
40. Sidhaye A, Cheskin LJ: Pharmacologic treatment of obesity. Adv Psychosom Med 2006, 27:42-52.
41. Silberstein SD: Topiramate in migraine prevention. Headache 2005, 45(Suppl 1):S57-S65.